11 Schoen Place
Pittsford, NY 14534
CellSelect Core Technology
CellTraffix has pioneered core platform technologies for the selection and manipulation of a broad range of Target Cells found in the bloodstream for modification, collection, or elimination. Target Cells include circulating tumor cells, adult stem cells, and immunological cells.
Unlike existing products that use antibodies or other molecular tools in non-physiologic approaches, the CellSelect system manipulates Target Cells by mimicking the mechanisms of cell trafficking employed by the body itself.
Real-time microscopic image of a common mode of cell trafficking in the body. Target Cells (in this case, leukocytes) are captured from the free stream and made to adhere to the blood vessel wall. The body facilitates capture and rolling of cells using the specialized adhesion protein Selectin. CellSelect technology mimics this mechanism of cell trafficking.
The core platform technology involves a flow-mediated adhesion system, built on a biocompatible device substrate. This system utilizes a class of molecules called selectins for adhering and rolling Target Cells either in vitro (in benchtop research kits or clinical diagnostics) or in vivo (in implantable devices), replicating the cellular trafficking mechanisms of the human body. Once Target Cells adhere and begin rolling, they can either be purified and removed, or therapeutically modified using a secondary set of Signalling Molecules commingled on the device surface.
Real-time image of CellSelect device capturing Target Cells from free-flow with Selectin. Cells undergo adhesion and rolling for either later harvest (for adult stem cell donation) or modification and release (for metastatic cancer cell killing).In the therapeutic applications, Target Cells are released from the device after modification and return to circulation. Key aspects of the core technology include proprietary cell capture coatings on the substrate, specialized tuning of the surface to adhere specific Target Cells, Target Cell rolling dynamics, prototype device design, and Cell Modification utilizing secondary Signalling Molecules.
Multi-step process of CellSelect technology: Target Cells in a blood or other biological sample specifically adhere to immobilized Adhesion Molecules affixed to the interior surface of the device. Optional secondary Signalling Molecules can cause the Target Cell to be therapeutically manipulated or killed. This powerful platform technology lends itself to the development of a wide range of potential products.
The ability of CellSelect technology to actively capture and manipulate Target Cells holds much promise for research grade and clinical kits, as well as therapeutic delivery systems for cancer metastasis, stem cell therapies, and immunological diseases.
For example, device substrates specifically tuned to adhere metastatic cancer cells also utilize apoptosis-inducing Signalling Molecules that result in the death of the metastatic cell after leaving the device surface. In this manner CellSelect technology opens significant opportunities for CellTraffix to become a leader in the large and growing oncology market against secondary tumor formation.
In additional cancer therapies, CellTraffix seeks to provide solutions for adult stem cell transplantation. CellSelect technology holds potential to provide modes of harvest and isolation of superior stem cell populations from Bone Marrow or Whole Blood donation product. Moreover, the ability of CellSelect to both adhere certain cell populations for harvest and therapeutically modify other cell populations with Signalling Molecules, means that CellSelect products will benefit both allogeneic and autologous recipients, whose risk involves either graft versus host disease (allogeneic) or reintroduction of cancer (autologous).
Schematic of CelTraffix prototype device for use in processing Bone Marrow donation following traditional cancer therapies. Bone Marrow or Whole Blood donation product is flowed through CellSelect device specially tuned to remove or initiate cell-death in undesired cells, including T-cells and Circulating Cancer Cells. Additionally, recent clinical advances in adult stem cell-based therapies such as the successful removal, reprogramming, and reintroduction of cells into a patient, highlight the powerful potential of adult stem cells as a new therapeutic target for a range of diseases, including diabetes and cardiovascular diseases.
CellTraffix is focused on continued development of its core technology to produce research and diagnostic kits targeting oncology and stem cell applications. These products have relatively low barriers to entry in terms of cost and time to market. The Company will also work towards developing a series of viable prototype devices (including both ex vivo and in vivo designs) for metastatic cancer prevention. We further plan to engage select pharmaceutical companies for partnering discussions to continue device development and fund product approval.
Partnerships with both academic and industrial/private sector entities contribute to ongoing development of CellSelect technologies.
For example, CellTraffix collaborates with the University of Rochester in key research activities including adhesion and isolation of Target Cell populations from mixed cell samples, induced killing of cancer cells, and development of superior surface chemistries for immobilization of adhesion molecules.
CellTraffix has recently completed proof-of-concept experiments in which prototype devices were successfully implanted into live rats, resulting in targeted capture and enrichment of viable adult stem cells from blood circulation. Results of these and other studies in prominent peer-reviewed journals provide excellent public exposure for CellTraffix’ patented CellSelect technologies.
CellTraffix has exclusively in-licensed a portfolio of patents, applications and know-how from both the University of Rochester and Biomed Solutions (investor in CellTraffix). The portfolio contains US patents and applications along with their corresponding international counterparts. The portfolio covers devices for adhering, rolling and modifying targeted cells. The Company plans to continue to file new patentable inventions as appropriate to protect its core technology.
CellTraffix plans to engage in commercial discussions with select parties once key development milestones are reached. The Company intends to pursue both co-development and/or joint-licensing relationships for therapeutic applications. This approach will yield financial benefits in the form of joint funding of programs, early upfront payments and milestones, and additionally allow CellTraffix to leverage the competencies of these partners.